You are here

Article info

Article menu

Download PDFPDF

Treatments
Viewpoint
Waiting for JAK inhibitor safety data

Authors

  • Tue Wenzel Kragstrup Department of Biomedicine, Aarhus University, Aarhus, DenmarkDiagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark PubMed articlesGoogle scholar articles
  • Bente Glintborg Department of Clinical Medicine, University of Copenhagen, Kobenhavn, DenmarkDANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, University Hospital of Copenhagen Rigshospitalet, Glostrup, Denmark PubMed articlesGoogle scholar articles
  • Annemarie L Svensson Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, University Hospital of Copenhagen Rigshospitalet, Glostrup, Denmark PubMed articlesGoogle scholar articles
  • Christopher McMaster Department of Rheumatology, Austin Health, Heidelberg, Victoria, AustraliaDepartment of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, AustraliaThe Centre for Digital Transformation of Health, University of Melbourne, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Philip C Robinson Faculty of Medicine, University of Queensland School of Clinical Medicine, Brisbane, Queensland, AustraliaDepartment of Rheumatology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia PubMed articlesGoogle scholar articles
  • Bent Deleuran Department of Biomedicine, Aarhus University, Aarhus, DenmarkDepartment of Rheumatology, Aarhus University Hospital, Aarhus, Denmark PubMed articlesGoogle scholar articles
  • David FL Liew Department of Rheumatology, Austin Health, Heidelberg, Victoria, AustraliaDepartment of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, AustraliaDepartment of Medicine, University of Melbourne, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Tue Wenzel Kragstrup; kragstrup{at}biomed.au.dk; Dr David FL Liew; david.liew{at}austin.org.au
View Full Text

Citation

Kragstrup TW, Glintborg B, Svensson AL, et al
Waiting for JAK inhibitor safety data
RMD Open 2022;8:e002236. doi: 10.1136/rmdopen-2022-002236

Publication history

  • Received January 24, 2022
  • Accepted February 4, 2022
  • First published February 23, 2022.
Online issue publication 
June 08, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.